Rate Video

ASH 2014 | ASH 2014: Novel treatments for mantle cell lymphoma

Jia Ruan • 5 Dec 2014

Mantle Cell Lymphoma Bortezomib Ibrutinib Lenalidomide

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel combination therapies that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab.

ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Jia Ruan • 5 Dec 2014

Romidepsin plus lenalidomide for patients with previously untreated PTCL

Jia Ruan • 10 Jun 2021

Unmet needs in T-cell lymphoma

Jia Ruan • 21 Oct 2021

Oral azacitidine plus CHOP for frontline PTCL treatment

Jia Ruan • 23 Nov 2020

Related Videos

The SHINE trial: controversies and unanswered questions

Graham Collins • 11 Jun 2022

Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL

Michael Wang • 11 Jun 2022

Novel agents in development for the treatment of MCL

Nilanjan Ghosh • 10 Jun 2022

ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL

Salim Yazji • 10 Jun 2022